SCHEDULE: Vanguard Group Reports Zero MacroGenics Stake After Realignment

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in MacroGenics Inc. following an internal realignment that disaggregated reporting responsibilities.

Summary

• The Vanguard Group filed an Amendment No. 6 to its Schedule 13G for MacroGenics Inc. Common Stock.
• The filing reports 0% beneficial ownership of MacroGenics Inc. Common Stock by The Vanguard Group.
• This change is a result of an internal realignment at The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• This disaggregated reporting is in accordance with SEC Release No. 34-39538, issued on January 12, 1998.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update from The Vanguard Group regarding its internal reporting structure, with no direct positive or negative implications for MacroGenics Inc.'s operational or financial performance.

Positives

• Enhanced clarity in beneficial ownership reporting due to The Vanguard Group's internal realignment, aligning with SEC guidance.

Negatives

• The Vanguard Group, Inc. no longer reporting beneficial ownership of MacroGenics Inc. Common Stock could be misinterpreted as a divestment, though it is an administrative reporting change.

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors. This specific amendment highlights an internal administrative change at The Vanguard Group, a major asset manager, regarding how its various entities report beneficial ownership, rather than a change in investment strategy towards MacroGenics Inc.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May initially perceive a major institutional investor's ownership dropping to 0% as negative, but understanding it's a reporting realignment should mitigate concerns.
• Regulatory Authorities: The filing ensures compliance with SEC reporting requirements for beneficial ownership.

Key Dates

Keywords

MacroGenics, Vanguard Group, Schedule 13G, beneficial ownership, SEC filing, institutional ownership, common stock, investment adviser, realignment